TOKYO, May 28 (Xinhua) Japanese automaker Toyota Motor Corp. announced on Friday that its global sales doubled from a year earlier in April to 859,448 units,
Vaccination commences in Galle, Matara and Kurunegala Hiru News Most visited website in Sri Lanka,Sri Lanka Latest news updates from Sri Lanka. Sri Lanka News updates and discussions. Welcome to the No1 online news Site for Sri Lankans. A Rayynor Silva Holdings Company
L aixecament de l estat d alarma i la supressió del toc de queda ha acabat de forma abrupta amb la tranquil·litat nocturna que regnava en alguns carrers i places cèntriques de la ciutat de Girona.
Two-axis Linear System for Precise and Fast Handling of Medical Laboratory Samples May 25 2021
A manufacturer of automated analytical equipment for medical technology is using a two-axis linear system to handle samples both quickly and precisely. To help meet sector demands for high performance, the system developer is taking advantage of an assembly based on two
NSK Monocarrier linear actuators. The units, which consist of a servo or stepper motor, ball screw and precision guide, arrive preassembled and ready for installation.
Key features of the NSK Monocarrier include high rigidity and load carrying capacity, smooth motion, precise positioning capability, corrosion resistance, and long service life. MCM series Monocarriers are available in five standard sizes with various stroke lengthsand pitches.
RepliCel Life Sciences, Inc.: RepliCel Launches Testing of Dermal Injector Units
VANCOUVER, BC / ACCESSWIRE / May 25, 2021 / RepliCel Life Sciences Inc. (TSX.V:RP) (OTCPK:REPCF) (FRA:P6P2) ( RepliCel or the Company ), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has received the first units of its dermal injector and is nearing completion of the preliminary phase of functional testing required to launch executing on the larger-scale production and testing plan. In our February update, we announced that manufacturing of RepliCel s initial batch of commercial-grade dermal injectors and related consumables was resuming and that, upon delivery of the first units, we would commence functional testing. I am pleased to report we have now entered this phase, stated RepliCel President and CEO, R. Lee Buckler.